Impaired BMPR2 signalling across pulmonary hypertension subgroups: a multicentre study, European Respiratory Journal Open Research, September 28, 2026

A multicentre German study, run at specialist centres in Heidelberg, Hannover and Giessen/Marburg, looked at the key gene in pulmonary hypertension, BMPR2. Changes in this gene cause most inherited cases of pulmonary arterial hypertension, and the biological pathway it controls is also the target of sotatercept. The researchers took blood samples from 234 people in […]

Impaired BMPR2 signalling across pulmonary hypertension subgroups: a multicentre study, European Respiratory Journal Open Research, September 28, 2026 Read Post »

Contemporary Economic, Hospitalization, and Mortality Burden Among Pulmonary Arterial Hypertension Patients: A Real-World US Claims Data Analysis, Pulmonary Circulation, October 6, 2026

A study using United States insurance claims data looked at the real-world burden of pulmonary arterial hypertension in 2,712 treated adults between 2017 and 2024 (average age 62, 69% women). Over an average follow-up of just over two years: The authors conclude that, despite recent advances in treatment, the disease still carries a heavy clinical

Contemporary Economic, Hospitalization, and Mortality Burden Among Pulmonary Arterial Hypertension Patients: A Real-World US Claims Data Analysis, Pulmonary Circulation, October 6, 2026 Read Post »

Gossamer submits New Drug Application to the US Food and Drug Administration (FDA) for seralutinib in pulmonary arterial hypertension (PAH)

Gossamer Bio has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for seralutinib in pulmonary arterial hypertension (PAH). A New Drug Application is the formal application requesting that the Food and Drug Administration review a medicine to determine whether it may be approved for use in patients. To be

Gossamer submits New Drug Application to the US Food and Drug Administration (FDA) for seralutinib in pulmonary arterial hypertension (PAH) Read Post »

Every Breath Counts: The Evolving Role of Inhaled Therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), European Medical Journal, October 20, 2026

This article contains an abstract and full transcript of a symposium which took place on 6th September 2026, as part of the European Respiratory Society (ERS) Congress held in Barcelona, Spain, sponsored by INSMED. The Chairperson was Professor Jean-Luc Vachiery and the speakers were Professors Irene Lang (Medical University, Vienna, Austria) Hossein Ardeschir Ghofrani (Giessen

Every Breath Counts: The Evolving Role of Inhaled Therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), European Medical Journal, October 20, 2026 Read Post »

Estimating mean pulmonary arterial pressure (mPAP) in the machine learning era, European Respiratory Journal, October 9, 2026

Accurate assessment of mean pulmonary arterial pressure (mPAP) is key to the diagnosis, haemodynamic classification and follow-up of pulmonary hypertension. The article, authored by French researcher at Le Kremlin-Bicêtre, France, requires permissions in order to access the full text, so we are only able to use the shareable abstract which reads “Large real-world datasets analysed

Estimating mean pulmonary arterial pressure (mPAP) in the machine learning era, European Respiratory Journal, October 9, 2026 Read Post »

Global data on pulmonary arterial hypertension in people aged 60 and over reveals diverging trajectories in rich and poor nations, Pulmonary Hypertension News, October 12, 2026

On October 12, 2026, Pulmonary Hypertension News published an article by Marisa Horak MS summarising the findings of a study by researchers at Ningxia Medical University in China, published in Pulmonary Circulation. The study looked at global data on pulmonary arterial hypertension in people aged 60 and over between 1990 and 2021. Worldwide, the researchers

Global data on pulmonary arterial hypertension in people aged 60 and over reveals diverging trajectories in rich and poor nations, Pulmonary Hypertension News, October 12, 2026 Read Post »

Treatment Strategies for Achieving and Maintaining Low-Risk Status in Pulmonary Arterial Hypertension: A Systematic Review, Cureus, October 18, 2026

Reaching and keeping low-risk status is now the main treatment goal in pulmonary arterial hypertension, but the evidence on which treatments help patients get there is spread across many studies using different risk tools. A systematic review was conducted by researchers in the UK following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

Treatment Strategies for Achieving and Maintaining Low-Risk Status in Pulmonary Arterial Hypertension: A Systematic Review, Cureus, October 18, 2026 Read Post »

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026

The pipeline VLR199 (the lead candidate): works in the same way as sotatercept (Winrevair), by trapping proteins of the activin family that drive the abnormal growth of cells in the lung vessels. The aim is to improve on aspects of sotatercept that may not be “fully optimised”. First clinical results showing whether it works are

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026 Read Post »

Join the European Pulmonary Fibrosis Federation (EU-PFF) and the Alliance for Pulmonary Hypertension for a webinar on pulmonary hypertension associated with interstitial lung disease (PH-ILD) on October 21, 2026, at 18:00.

On 21 October at 18:00 CET, join the European Pulmonary Fibrosis Federation (EU-PFF) and the Alliance for Pulmonary Hypertension for a webinar titled “Together for PH-ILD: Strengthening Awareness, Care, and Patient Support”. The webinar will bring together clinicians and patient advocates to discuss how cross-collaboration can improve awareness, care and support for people living with

Join the European Pulmonary Fibrosis Federation (EU-PFF) and the Alliance for Pulmonary Hypertension for a webinar on pulmonary hypertension associated with interstitial lung disease (PH-ILD) on October 21, 2026, at 18:00. Read Post »

Evolving profile and outcomes of patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation in France, Journal of Heart and Lung Transplant, September 3, 2026

A study published in Journal of Heart and Lung Transplant Open by a large French team looked at all 241 patients with pulmonary arterial hypertension who had a lung or heart-lung transplant in France between 2008 and 2023. Using data from the national registries for the disease and for transplants, the authors compared two periods:

Evolving profile and outcomes of patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation in France, Journal of Heart and Lung Transplant, September 3, 2026 Read Post »

Update on the global Phase IIb EPIMODE trial evaluating drug candidate CS1 in pulmonary arterial hypertension (PAH), Modular Finance, October 8, 2026

EPIMODE is a global, randomized and placebo-controlled Phase IIb trial designed to evaluate efficacy, safety and tolerability, determine the optimal dose for further development, and provide additional insight into CS1’s potential disease-modifying effects in patients with pulmonary arterial hypertension (PAH). CS1 is being developed by Cereno Scientific as an oral, once-daily, potentially disease-modifying treatment for

Update on the global Phase IIb EPIMODE trial evaluating drug candidate CS1 in pulmonary arterial hypertension (PAH), Modular Finance, October 8, 2026 Read Post »

“European Reference Networks: A success story for patients living with a rare disease”, new booklet just issued by the EU Commission

The European Commission has published a booklet celebrating the European Reference Networks, which since 2017 have connected rare disease experts across Europe so that no patient is left behind, wherever they live. Through real-life stories, it shows how the 24 networks have changed patients’ lives: from long-awaited diagnoses to pioneering treatments, research advances and closer

“European Reference Networks: A success story for patients living with a rare disease”, new booklet just issued by the EU Commission Read Post »

October 10 2026 is the Council of Europe’s “European Day for Organ Donation and Transplantation”, the host country this year is Cyprus

October 10, is the European Day for Organ Donation and Transplantation. Created in 1996 by the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe. It’s aim is to raise public awareness of the need for organ, tissue and cell donation, promote voluntary and unpaid donation, and honour donors and healthcare

October 10 2026 is the Council of Europe’s “European Day for Organ Donation and Transplantation”, the host country this year is Cyprus Read Post »

What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026

September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice

What’s new on the Pulmonary Hypertension Knowledge Platform – September 2026 Read Post »

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension

Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and Chair of the Dutch pulmonary hypertension foundation, attended both the European Society of Cardiology and the European Respiratory Society (ERS) Annual Congresses 2026 taking place respectively in Munich, Germany (August 28-30), and Barcelona, Spain (September 5-9). Based on the sessions she followed, she has

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension Read Post »

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026

We are thrilled to release five brand-new “Patients Empowering Patients” talks — five women, three countries (Italy, Turkey, the US), and five very different stories, all united by the same resilience and positive outlook that defines this community. From Aygün Mengelli Tomur’s lung transplant journey “From Waiting to Breathing: A New Beginning,” to Deger Kesimogluğlu’s

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026 Read Post »

Patients and Advocates Call on US Congress to Pass Life-Changing Oxygen Reform Before End of Year

Patients, caregivers and advocates across the US are calling for passage of the SOAR Act (Supplemental Oxygen Access Reform Act), a bipartisan bill aimed at improving access to supplemental oxygen for over 1.5 million Americans with serious lung and heart conditions — including portable, high-flow liquid oxygen, which is often unreliable, delayed, or simply unavailable under current

Patients and Advocates Call on US Congress to Pass Life-Changing Oxygen Reform Before End of Year Read Post »

US Food and Drug Administration (FDA) updates Winrevair (sotatercept) label based on new trial data supporting earlier use in pulmonary arterial hypertension

The US Food and Drug Administration (FDA) has approved an update to the US label for WINREVAIR (sotatercept-csrk), Merck’s activin signaling inhibitor for pulmonary arterial hypertension, to include efficacy and safety data from the Phase 3 HYPERION trial. The trial specifically evaluated adults newly diagnosed with pulmonary arterial hypertension — within 12 months of screening,

US Food and Drug Administration (FDA) updates Winrevair (sotatercept) label based on new trial data supporting earlier use in pulmonary arterial hypertension Read Post »

Join our prestigious panel of speakers on September 28 at 6 pm CEST to gain expert insights on how the new advances in science and AI can improve pulmonary arterial hypertension care!

The Alliance for Pulmonary Hypertension (AfPH) is back with the third instalment of their 2026 webinar series exploring how new science and AI are transforming pulmonary arterial hypertension care. This session taking place on September 28 at 6 pm CEST brings together leading experts from the US, UK, and Netherlands to explore where the field

Join our prestigious panel of speakers on September 28 at 6 pm CEST to gain expert insights on how the new advances in science and AI can improve pulmonary arterial hypertension care! Read Post »

A New Breath: Aygün’s Lung Transplant and Organ Donation Story | PEP Talk Transcript

Hello, my name is Aygün. I am breathing today with the lungs of a deceased person who donated five vital organs. I am endlessly grateful—truly, a thousand times grateful—to my late donor and to the generous family who donated their organs. I was born with lung disease. It continued throughout my childhood and into adulthood. Although

A New Breath: Aygün’s Lung Transplant and Organ Donation Story | PEP Talk Transcript Read Post »

TRANSLATE »
Scroll to Top